C. Sessa

1.6k total citations · 1 hit paper
24 papers, 1.1k citations indexed

About

C. Sessa is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, C. Sessa has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Reproductive Medicine and 6 papers in Molecular Biology. Recurrent topics in C. Sessa's work include Ovarian cancer diagnosis and treatment (8 papers), Cancer Treatment and Pharmacology (5 papers) and Lung Cancer Research Studies (5 papers). C. Sessa is often cited by papers focused on Ovarian cancer diagnosis and treatment (8 papers), Cancer Treatment and Pharmacology (5 papers) and Lung Cancer Research Studies (5 papers). C. Sessa collaborates with scholars based in Switzerland, Italy and United Kingdom. C. Sessa's co-authors include J. Wanders, H. Franklin, Stuart Kaye, Nicoletta Colombo, Jonathan A. Ledermann, Aarón Sulkes, Joan A. Smyth, J. B. Vermorken, Jaap Verweij and M. Castiglione and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

C. Sessa

24 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

2019 259 citations Nicoletta Colombo, C. Sessa et al. International Journal of Gynecological Cancer profile →

Peers

Countries citing papers authored by C. Sessa

Since Specialization

Citations

This map shows the geographic impact of C. Sessa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Sessa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Sessa more than expected).

Fields of papers citing papers by C. Sessa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Sessa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Sessa. The network helps show where C. Sessa may publish in the future.

Co-authorship network of co-authors of C. Sessa

This figure shows the co-authorship network connecting the top 25 collaborators of C. Sessa. A scholar is included among the top collaborators of C. Sessa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Sessa. C. Sessa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective 2021 ·ESMO Open ·C. Sessa, Javier Cortés, Pierfranco Conté, Fátima Cardoso, Toni K. Choueiri, Reinhard Dummer, Patricia LoRusso, Oliver G. Ottmann, Bettina Ryll, Tony Mok, Margaret A. Tempero, Silvia Comis, Cristina Oliva, Solange Peters, Josep Tabernero	25
2	ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease breakdown → 2019 ·International Journal of Gynecological Cancer ·Nicoletta Colombo, C. Sessa, Andreas du Bois, Jonathan A. Ledermann, W. Glenn McCluggage, Iain A. McNeish, Philippe Morice, Sandro Pignata, I. L. Ray-Coquard, Ignace Vergote, Thaïs Baert, I. Belaroussi, (unknown), Siel Olbrecht, François Planchamp, Denis Querleu	259
3	Abstract CT014: A large phase I study of TAS-114 in combination with S-1 in patients with advanced solid tumors 2018 ·Cancer Research ·Angelica Fasolo, (unknown), Anastasios Stathis, C. Sessa, Antoine Hollebecque, Jean Charles Soria, Alberto F. Sobrero, Jean‐Luc Van Laethem, Kunihiro Yoshisue, (unknown)	4
4	appendix 7: Ovarian cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Gynaecological-Malignancies) 2016 ·Annals of Oncology ·Jonathan A. Ledermann, C. Sessa, N. Colombo	6
5	An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib 2016 ·Targeted Oncology ·Joaquı́n Mateo, Víctor Moreno, Avinash Gupta, S.B. Kaye, Emma Dean, Mark R. Middleton, Michael Friedländer, Charlie Gourley, Ruth Plummer, Gordon Rustin, C. Sessa, Karin Leunen, Jonathan A. Ledermann, Helen Swaisland, Anitra Fielding, Wendy Bannister, Shibani Nicum, L Rhoda Molife	104
6	Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968) 2015 ·British Journal of Clinical Pharmacology ·Markus Joerger, Dagmar Hess, Angelo Delmonte, Elisa Gallerani, Angelica Fasolo, Luca Gianni, Sara Cresta, P. Barbieri, Silvia Pace, C. Sessa	10
7	Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors 2015 ·Investigational New Drugs ·Markus Joerger, Dagmar Hess, Angelo Delmonte, Elisa Gallerani, P. Barbieri, Silvia Pace, C. Sessa	9
8	SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity. 2012 ·Blood ·Christoph Driessen, Dagmar Hess, Thomas Pabst, Sarah R. Haile, Markus Joerger, Roger von Moos, Catherine Berset, Susanne Crowe, Hilde Rosing, Herman S. Overkleeft, C. Sessa, Marianne Kraus	1
9	Update on PARP1 inhibitors in ovarian cancer 2011 ·Annals of Oncology ·C. Sessa	29
10	Bevacizumab in the primary treatment of epithelial ovarian cancer – some comments on the latest results 2011 ·Zurich Open Repository and Archive (University of Zurich) ·Chahin Achtari, (unknown), (unknown), Jens Huober, (unknown), Patrick Petignat, Roger von Moos, C. Sessa	1
11	Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2010 ·Annals of Oncology ·Nicoletta Colombo, Michele Peiretti, Gabriella Parma, M. Lapresa, Rosanna Mancari, Silvestro Carinelli, C. Sessa, M. Castiglione	146
12	Clinical development of namitecan (ST1968), a novel camptothecin derivative with high antitumor activity: Phase I clinical data 2009 ·Journal of Clinical Oncology ·Dagmar Hess, (unknown), Angelo Delmonte, Elisa Gallerani, P. Barbieri, Silvia Pace, Paolo Carminati, Silvia Marsoni, N. Coceani, C. Sessa	3
13	Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer 2008 ·Journal of Thoracic Oncology ·Petr Zatloukal, Radj Gervais, Johan Vansteenkiste, Leon Bosquée, C. Sessa, Étienne Brain, Éric Dansin, T. Urban, Nadine Dohollou, M Besenval, Élisabeth Quoix	22
14	Phase I study of intravenous (IV) milataxel in adult patients with advanced malignant tumors 2006 ·Journal of Clinical Oncology ·Emmanuelle Bourbouloux, Mario Campone, J. B. Vermorken, (unknown), C. Sessa, Antonella Perotti	3
15	5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)–cisplatin in advanced gastric carcinoma: a phase I–II trial 2004 ·Annals of Oncology ·A Roth, Rudolf Maibach, Nicola Fazio, C. Sessa, Roger Stupp, R. Morant, Richard Herrmann, Markus Borner, Aron Goldhirsch, Filippo de Braud	36
16	Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer 2000 ·Annals of Oncology ·Tommaso De Pas, Filippo de Braud, Romano Danesi, C. Sessa, Chiara Catania, Giuseppe Curigliano, Stefano Fogli, Mario Del Tacca, (unknown), Alberto Sbanotto, Andrea Rocca, Saverio Cinieri, (unknown), Andrea Milani, Aron Goldhirsch	25
17	Gemcitabine in the treatment of ovarian cancer 1999 ·Annals of Oncology ·Steen Werner Hansen, Malgorzata Tuxen, C. Sessa	4
18	Activity of docetaxel (Taxotere) in small cell lung cancer 1994 ·European Journal of Cancer ·J F Smyth, I E Smith, C. Sessa, Patrick Schöffski, J. Wanders, H. Franklin, Stuart Kaye	105
19	Docetaxel (TaxotereTM) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group 1994 ·British Journal of Cancer ·Aarón Sulkes, Joan A. Smyth, C. Sessa, (unknown), J. B. Vermorken, Stuart Kaye, J. Wanders, H. Franklin, (unknown), Jaap Verweij	198
20	Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy 1988 ·Cancer ·Aron Goldhirsch, Richard Greiner, E. Dreher, C. Sessa, F. Krauer, M. Forni, (unknown), Kurt Brunner, (unknown), (unknown), Serge Leyvraz, P Siegenthaler, E Gloor, K. Buser, RD Gelber, (unknown)	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact